Eli Lilly and (LLY)

Insider buying is one of the few market signals that does not hide behind algorithms or price targets.

Recent breakthroughs in artificial intelligence (AI) are producing tangible results, and not just in the tech industry, although companies in that sector tend to dominate the AI headlines. Even in hea...

Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.

Two of the hottest healthcare stocks in recent years have been Novo Nordisk (NVO 6.10%) and Eli Lilly (LLY 0.46%). The former has risen by 400% in the past five years, while the latter is up 67%.

The U.S. Food and Drug Administration's recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.

Novo Nordisk A/S NVO presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.

If you want a good dividend growth stock to buy and not worry about, look no further. The three stocks that I've listed here have tremendous long-term growth prospects, offer great dividends, and have...

Eli Lilly's Mounjaro helped children and adolescents aged 10 to 17 years with type 2 diabetes manage their blood sugar better and lose weight, according to trial results presented at a medical meeting...

Eli Lilly and Company's hot streak of obesity and type 2 diabetes readouts ended in early August when we saw underwhelming top-line phase 3 results of orforglipron in obesity patients. Orforglipron lo...

Eli Lilly will invest $5B in a new Virginia plant to make cancer drugs, creating 650 jobs amid Trump's tariff push.